May 31 | 2022

Strengthening the IndiTreat® distribution in North Europe

Read more
May 24 | 2022

Kommuniké från årsstämma i 2cureX AB

Read more
May 24 | 2022

2cureX publishes interim report for the first quarter 2022

Read more
May 24 | 2022

2cureX offentliggör delårsrapport för det första kvartalet 2022

Read more
May 20 | 2022

We invite you to join the 2cureX Q1 Report webcast and Q&A session at 15:00 on 24 May, 2022

Read more
May 17 | 2022

Three IndiTreat® posters have been accepted at ESMO-GI 2022

Read more
May 12 | 2022

2cureX AB nominates Dr. Michael Schaefer to the Board of Directors

Read more
May 12 | 2022

2cureX AB nominerar Dr. Michael Schaefer till styrelsen

Read more
May 11 | 2022

IGNITE update – Eight hospitals have been enrolled in the program

Read more
May 9 | 2022

2cureX presents IndiTreat® clinical results at the Society for Functional Precision Medicine

Read more
May 6 | 2022

2cureX appoints Sedermera Corporate Finance AB to act as a liquidity provider for the Company´s share

Read more
May 6 | 2022

2cureX utser Sedermera Corporate Finance AB till likviditetsgarant för bolagets aktie

Read more
May 5 | 2022

Redeye research interview with 2cureX CEO, Fernando Andreu

Read more
May 3 | 2022

2cureX offentliggör årsredovisning för räkenskapsåret 2021

Read more
May 3 | 2022

2cureX publishes the annual report for the fiscal year 2021

Read more
April 29 | 2022

Rättelse: Korrektion till “Kallelse till årsstämma i 2cureX AB” utfärdad den 21 april 2022

Read more
April 22 | 2022

Korrektion till “Kallelse till årsstämma i 2cureX AB” utfärdad den 21 april 2022

Read more
April 22 | 2022

Correction of “Notice of annual general meeting of 2cureX AB (publ)” issued on 21st April 2022

Read more